SK2694A3 - Pharmaceutical agent for treatment of motor neuron diseases - Google Patents
Pharmaceutical agent for treatment of motor neuron diseases Download PDFInfo
- Publication number
- SK2694A3 SK2694A3 SK26-94A SK2694A SK2694A3 SK 2694 A3 SK2694 A3 SK 2694A3 SK 2694 A SK2694 A SK 2694A SK 2694 A3 SK2694 A3 SK 2694A3
- Authority
- SK
- Slovakia
- Prior art keywords
- bdnf
- motor neurons
- motor
- ngf
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Physical Water Treatments (AREA)
- Water Treatment By Electricity Or Magnetism (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Water Treatment By Sorption (AREA)
- Medicines Containing Plant Substances (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72770491A | 1991-07-10 | 1991-07-10 | |
| PCT/US1992/004228 WO1993001300A1 (fr) | 1991-07-10 | 1992-05-19 | Methodes de traitement de maladies des neurones moteurs utilisant des elements de la famille des molecules bdnf/nt-3/ngf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK2694A3 true SK2694A3 (en) | 1995-02-08 |
Family
ID=24923677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK26-94A SK2694A3 (en) | 1991-07-10 | 1992-05-19 | Pharmaceutical agent for treatment of motor neuron diseases |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP0755682A1 (fr) |
| JP (1) | JPH06509094A (fr) |
| CN (1) | CN1065768C (fr) |
| AT (1) | ATE202939T1 (fr) |
| AU (2) | AU675409B2 (fr) |
| CA (1) | CA2113083A1 (fr) |
| DE (1) | DE69231930T2 (fr) |
| DK (1) | DK0593516T3 (fr) |
| ES (1) | ES2157903T3 (fr) |
| FI (1) | FI940098A (fr) |
| GR (1) | GR3036776T3 (fr) |
| HU (1) | HUT70275A (fr) |
| IE (1) | IE921602A1 (fr) |
| IL (1) | IL101928A0 (fr) |
| NO (1) | NO940084L (fr) |
| PT (1) | PT100501A (fr) |
| RU (1) | RU94016525A (fr) |
| SK (1) | SK2694A3 (fr) |
| WO (1) | WO1993001300A1 (fr) |
| ZA (1) | ZA923639B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07509600A (ja) * | 1992-06-12 | 1995-10-26 | リジェネロン ファーマシューティカルズ，インコーポレーテッド | ニューロトロフィン−４発現に基づく治療および診断法 |
| FR2717496B1 (fr) * | 1994-03-18 | 1996-04-12 | Rhone Poulenc Rorer Sa | Virus recombinants, préparation et utilisation en thérapie génique. |
| CN1112215C (zh) * | 1999-12-28 | 2003-06-25 | 潘晓东 | 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途 |
| EP1278537B1 (fr) * | 2000-05-05 | 2009-01-14 | The Research Foundation Of the City university of New York | Compositions de stimulation de la regeneration et de la reparation du systeme nerveux par regulation de l'activite de l'arginase 1 et de la synthese des polyamines |
| WO2006055685A2 (fr) * | 2004-11-17 | 2006-05-26 | Neuralstem, Inc. | Transplantation de cellules neurales humaines pour traiter des troubles neurodegeneratifs |
| WO2008156418A1 (fr) * | 2007-06-19 | 2008-12-24 | Astrazeneca Ab | Procédé de criblage ou de diagnostic du syndrome de post-poliomyélite et de la fibromyalgie |
| WO2009023540A1 (fr) * | 2007-08-10 | 2009-02-19 | Regeneron Pharmaceuticals, Inc. | Anticorps humains anti-facteur de croissance nerveux humain de haute affinité |
| WO2014111525A2 (fr) | 2013-01-18 | 2014-07-24 | Anaxomics Biotech, Sl | Nouvelles polythérapies pour le traitement de maladies du système nerveux |
| US10349890B2 (en) | 2015-06-26 | 2019-07-16 | C. R. Bard, Inc. | Connector interface for ECG-based catheter positioning system |
| WO2023164311A2 (fr) * | 2022-02-28 | 2023-08-31 | Bioincept, Llc | Compositions et méthodes de traitement de la sclérose latérale amyotrophique (sla) et de troubles associés |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923696A (en) * | 1987-05-04 | 1990-05-08 | Baylor College Of Medicine | Method to prepare a neurotrophic composition |
| IL95511A (en) * | 1989-08-30 | 2000-10-31 | Max Planck Gesellschaft | Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor |
| US5229500A (en) * | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
| IE903130A1 (en) * | 1989-09-15 | 1991-03-27 | Regeneron Pharma | Ciliary neurotrophic factor |
-
1992
- 1992-05-19 ZA ZA923639A patent/ZA923639B/xx unknown
- 1992-05-19 EP EP96111711A patent/EP0755682A1/fr not_active Withdrawn
- 1992-05-19 DE DE69231930T patent/DE69231930T2/de not_active Expired - Lifetime
- 1992-05-19 HU HU9400063A patent/HUT70275A/hu unknown
- 1992-05-19 EP EP92912453A patent/EP0593516B1/fr not_active Expired - Lifetime
- 1992-05-19 IL IL101928A patent/IL101928A0/xx unknown
- 1992-05-19 JP JP5502202A patent/JPH06509094A/ja active Pending
- 1992-05-19 SK SK26-94A patent/SK2694A3/sk unknown
- 1992-05-19 PT PT100501A patent/PT100501A/pt not_active Application Discontinuation
- 1992-05-19 WO PCT/US1992/004228 patent/WO1993001300A1/fr active IP Right Grant
- 1992-05-19 AU AU20095/92A patent/AU675409B2/en not_active Ceased
- 1992-05-19 ES ES92912453T patent/ES2157903T3/es not_active Expired - Lifetime
- 1992-05-19 AT AT92912453T patent/ATE202939T1/de not_active IP Right Cessation
- 1992-05-19 RU RU94016525/14A patent/RU94016525A/ru unknown
- 1992-05-19 CN CN92105070A patent/CN1065768C/zh not_active Expired - Fee Related
- 1992-05-19 DK DK92912453T patent/DK0593516T3/da active
- 1992-05-19 CA CA2113083A patent/CA2113083A1/fr not_active Abandoned
- 1992-07-01 IE IE160292A patent/IE921602A1/en not_active Application Discontinuation
-
1994
- 1994-01-10 FI FI940098A patent/FI940098A/fi not_active Application Discontinuation
- 1994-01-10 NO NO940084A patent/NO940084L/no unknown
-
1996
- 1996-11-08 AU AU70676/96A patent/AU7067696A/en not_active Abandoned
-
2001
- 2001-10-03 GR GR20010401637T patent/GR3036776T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2113083A1 (fr) | 1993-01-21 |
| GR3036776T3 (en) | 2002-01-31 |
| DE69231930T2 (de) | 2002-04-11 |
| FI940098A0 (fi) | 1994-01-10 |
| WO1993001300A1 (fr) | 1993-01-21 |
| NO940084L (no) | 1994-03-08 |
| EP0593516A1 (fr) | 1994-04-27 |
| EP0755682A1 (fr) | 1997-01-29 |
| FI940098A (fi) | 1994-03-10 |
| CN1065768C (zh) | 2001-05-16 |
| IE921602A1 (en) | 1993-01-13 |
| DK0593516T3 (da) | 2001-09-17 |
| PT100501A (pt) | 1993-09-30 |
| ZA923639B (en) | 1993-02-24 |
| HU9400063D0 (en) | 1994-06-28 |
| AU2009592A (en) | 1993-02-11 |
| ES2157903T3 (es) | 2001-09-01 |
| JPH06509094A (ja) | 1994-10-13 |
| CN1071585A (zh) | 1993-05-05 |
| HUT70275A (en) | 1995-09-28 |
| AU7067696A (en) | 1997-01-16 |
| NO940084D0 (no) | 1994-01-10 |
| AU675409B2 (en) | 1997-02-06 |
| ATE202939T1 (de) | 2001-07-15 |
| IL101928A0 (en) | 1992-12-30 |
| RU94016525A (ru) | 1996-06-10 |
| EP0593516B1 (fr) | 2001-07-11 |
| EP0593516A4 (fr) | 1995-01-18 |
| DE69231930D1 (de) | 2001-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hagg et al. | Ciliary neurotrophic factor prevents neuronal degeneration and promotes low affinity NGF receptor expression in the adult rat CNS | |
| Sjöberg et al. | Insulin-like growth factor (IGF-1) as a stimulator of regeneration in the freeze-injured rat sciatic nerve | |
| Mantyh et al. | Beta 2-adrenergic receptors are expressed by glia in vivo in the normal and injured central nervous system in the rat, rabbit, and human | |
| EP0890105B1 (fr) | Méthods pour le diagnostique, pour la production des médicaments et pour le criblage de substances relatives à la maladie d'Alzheimer et des peptides derivés de l'amyloid beta | |
| Burke et al. | Loss of developing cholinergic basal forebrain neurons following excitotoxic lesions of the hippocampus: rescue by neurotrophins | |
| DE69633336T2 (de) | Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält | |
| CA2040404A1 (fr) | Facteur neurotropique ciliaire | |
| Brecknell et al. | Functional and anatomical reconstruction of the 6-hydroxydopamine lesioned nigrostriatal system of the adult rat | |
| Herrero et al. | GM-1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys | |
| Wen et al. | Protective effect of basic fibroblast growth factor-heparin and neurotoxic effect of platelet factor 4 on ischemic neuronal loss and learning disability in gerbils | |
| SK2694A3 (en) | Pharmaceutical agent for treatment of motor neuron diseases | |
| Knusel et al. | Intraparenchymal NGF injections in adult and aged rats induce long-lasting Trk tyrosine phosphorylation | |
| Albeck et al. | Acute application of NGF increases the firing rate of aged rat basal forebrain neurons | |
| Blum et al. | Chronic continuous infusion of (−) nicotine reduces basic fibroblast growth factor messenger RNA levels in the ventral midbrain of the intact but not of the 6-hydroxydopamine-lesioned rat | |
| Gu et al. | Responses in the aged rat brain after total immunolesion | |
| JP3049091B2 (ja) | ニューロン増殖及び維持を調節する方法 | |
| JOOSTEN et al. | Alpha-melanocyte stimulating hormone promotes regrowth of injured axons in the adult rat spinal cord | |
| AU738192B2 (en) | Neuronal rescue agent | |
| WO1992010200A1 (fr) | Interactions fonctionnelles entre un glial s-100b et des neurones serotoninergiques du systeme nerveux central | |
| WO1994020125A1 (fr) | Traitement des affections des neurones moteurs a l'aide du facteur de croissance des fibroblastes 5 (fgf-5) | |
| Wagey et al. | Phosphatidylinositol 3-kinase activity in murine motoneuron disease: the progressive motor neuropathy mouse | |
| US20070015707A1 (en) | Neuroprotective effect of activin in animals exposed to hypoxia/ischemia | |
| Ferguson et al. | Chicken NGF and non‐NGF trophic factor synthesis and release by sciatic nerves in vitro | |
| WO1993009798A1 (fr) | Methodes therapeutiques et diagnostiques basees sur l'expression de nt-3 specifique de tissus et sur la liaison de recepteurs | |
| AU9676598A (en) | Apolipoprotein e/growth factor complexes and methods of use |